PLUS Therapeutics (PSTV) CFO converts RSUs into 2,985 common shares

Q: What insider transactions did PSTV’s CFO report in this Form 4?

The CFO of PLUS THERAPEUTICS (PSTV) reported equity compensation-related transactions. On July 1, 2026, he exercised or converted derivative awards into 2,985 shares of common stock at a stated price of $0.0000 per share , reflecting non-cash vesting of awards.

Q: Were the PSTV CFO’s July 1, 2026 transactions open-market buys or sells?

No, the transactions were coded “ M ” for option or derivative exercises, not open-market buys or sells. They represent the conversion of equity awards, including RSUs, into common shares as part of the company’s compensation program rather than discretionary market trading.

Q: How do the PLUS THERAPEUTICS RSU grants for the CFO vest over time?

Footnotes state the CFO’s RSU grants vest in twelve substantially equal quarterly installments . The three referenced grants begin vesting on October 1, 2025 , April 1, 2026 , and July 1, 2026 , respectively, with each RSU converting into one share of common stock when vested.

Q: What does the M transaction code mean in the PSTV CFO’s Form 4?

The M transaction code indicates an exercise or conversion of a derivative security , such as options or RSUs, into common stock. It is not classified as a market buy or sell, but rather as the use of existing equity awards granted under compensation plans.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. Chief Financial Officer Andrew John Hugh MacIntyre Sims reported equity compensation-related transactions in the company’s common stock. On July 1, 2026, he exercised or converted derivative awards into a total of 2,985 shares of common stock at a stated price of $0.0000 per share, reflecting non-cash vesting of awards.

The filing shows his direct holdings of common stock at 9,941 shares after one of the transactions, with 28,522 restricted stock units (RSUs) remaining after another. Footnotes state that each RSU represents a right to one common share and that the RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026, respectively. These transactions appear to be part of scheduled RSU vesting rather than open-market buying or selling.

Insider Trade Summary

2,985 shares exercised/converted

Mixed 6 txns

Insider Sims Andrew John Hugh MacIntyre

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,533	$0.00	--
Exercise	Restricted Stock Units	1,165	$0.00	--
Exercise	Restricted Stock Units	287	$0.00	--
Exercise	Common Stock	1,533	$0.00	--
Exercise	Common Stock	1,165	$0.00	--
Exercise	Common Stock	287	$0.00	--

Holdings After Transaction: Restricted Stock Units — 28,522 shares (Direct, null); Common Stock — 8,489 shares (Direct, null)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

Key Figures

Common shares from exercises: 2,985 shares Individual exercise 1: 287 shares Individual exercise 2: 1,165 shares +4 more

7 metrics

Common shares from exercises 2,985 shares Total derivative exercises on July 1, 2026

Individual exercise 1 287 shares Common Stock acquired via code M on July 1, 2026

Individual exercise 2 1,165 shares Common Stock acquired via code M on July 1, 2026

Individual exercise 3 1,533 shares Common Stock acquired via code M on July 1, 2026

Price per share $0.0000 per share Stated transaction price for the common stock entries

Common shares held 9,941 shares Total shares of Common Stock following one transaction

RSUs remaining 28,522 RSUs Restricted Stock Units following one derivative transaction

Key Terms

Restricted Stock Unit, RSU, derivative security, quarterly installments

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

quarterly installments financial

"occurs in twelve substantially equal quarterly installments beginning on October 1, 2025"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:30 PM Accepted by SEC EDGAR 07/01/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sims Andrew John Hugh MacIntyre

(Last)

(First)

(Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON

TEXAS

77021

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		M		1,533⁽²⁾	A	$0⁽¹⁾	8,489	D
Common Stock	07/01/2026		M		1,165⁽³⁾	A	$0⁽¹⁾	9,654	D
Common Stock	07/01/2026		M		287⁽⁴⁾	A	$0⁽¹⁾	9,941	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	07/01/2026		M			1,533	⁽²⁾	⁽²⁾	Common Stock	1,533	$0	28,522	D
Restricted Stock Units	$0	07/01/2026		M			1,165	⁽³⁾	⁽³⁾	Common Stock	1,165	$0	27,357	D
Restricted Stock Units	$0	07/01/2026		M			287	⁽⁴⁾	⁽⁴⁾	Common Stock	287	$0	27,070	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.

3. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.

4. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

	Andrew Sims, as attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did PSTV’s CFO report in this Form 4?

The CFO of PLUS THERAPEUTICS (PSTV) reported equity compensation-related transactions. On July 1, 2026, he exercised or converted derivative awards into 2,985 shares of common stock at a stated price of $0.0000 per share, reflecting non-cash vesting of awards.

Were the PSTV CFO’s July 1, 2026 transactions open-market buys or sells?

No, the transactions were coded “M” for option or derivative exercises, not open-market buys or sells. They represent the conversion of equity awards, including RSUs, into common shares as part of the company’s compensation program rather than discretionary market trading.

How many PLUS THERAPEUTICS shares did the CFO acquire through exercises?

The Form 4 shows the CFO exercised or converted derivative awards into 2,985 shares of PLUS THERAPEUTICS common stock. Individual transactions were for 287, 1,165, and 1,533 shares, all recorded on July 1, 2026, at a stated price of $0.0000 per share.

What are the CFO’s reported holdings after these PSTV transactions?

Following the reported transactions, one line shows the CFO directly holding 9,941 shares of PLUS THERAPEUTICS common stock. Another line shows 28,522 restricted stock units (RSUs) remaining, each RSU representing a contingent right to receive one share of common stock.

How do the PLUS THERAPEUTICS RSU grants for the CFO vest over time?

Footnotes state the CFO’s RSU grants vest in twelve substantially equal quarterly installments. The three referenced grants begin vesting on October 1, 2025, April 1, 2026, and July 1, 2026, respectively, with each RSU converting into one share of common stock when vested.

What does the M transaction code mean in the PSTV CFO’s Form 4?

The M transaction code indicates an exercise or conversion of a derivative security, such as options or RSUs, into common stock. It is not classified as a market buy or sell, but rather as the use of existing equity awards granted under compensation plans.